Skip Navigation

For U.S. Healthcare Professionals

Patient.

Resources

Information
to Help You
and Your Patients

Healthcare professional.

For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough or cannot be tolerated.

Back to Resources list

Clinical Reprints

Read about Entyvio in articles from Gut, an International Journal of Gastroenterology and Hepatology, the New England Journal of Medicine, and Alimentary Pharmacology & Therapeutics.

These articles are provided by Takeda for discussion of FDA approved uses.
Vedolizumab should be used only according to the accompanying complete prescribing information.

Landmark study

Vedolizumab vs adalimumab for moderate to severe ulcerative colitis—the VARSITY study

The New England Journal of Medicine

VARSITY—the first head-to-head study of biologic therapies for moderate to severe ulcerative colitis.1,2

Read Full Text

The safety of vedolizumab for ulcerative colitis and Crohn's disease

Gut: An International Journal of Gastroenterology and Hepatology

A study assessing the safety profile of vedolizumab in over 2800 patients over an extended period of time.3

Read Full Text

Vedolizumab as induction and maintenance therapy for ulcerative colitis

The New England Journal of Medicine

A study evaluating the efficacy and safety of vedolizumab in adult patients with moderately to severely active ulcerative colitis.4

Read Full Text

Long-term safety of vedolizumab therapy for inflammatory bowel disease

Alimentary Pharmacology & Therapeutics

A final analysis of the long‑term safety results of vedolizumab treatment of up to 7 years in over 2200 patients with moderate to severely active UC or CD.5

Read Full Text

References:

  1. Data on file. Takeda Pharmaceuticals.
  2. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. N Engl J Med. 2019;381(13):1215-1226.
  3. Colombel JF, Sands BE, Rutgeerts P, et al. Gut. 2017;66(5):839-851.
  4. Feagan BG, Rutgeerts P, Sands BE, et al; for the GEMINI 1 Study Group. N Engl J Med. 2013;369(8):699-710.
  5. Loftus EV, Feagan BG, Panaccione R, et al; for the GEMINI LTS study team. Aliment Pharmacol Ther. 2020;00:1-13.